Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel - Bristol-Myers Squibb

Drug Profile

Paclitaxel - Bristol-Myers Squibb

Alternative Names: BMS-181339; BMY 45622; NSC-673089; Taxol

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Bristol-Myers Squibb; University of Washington
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer
  • Phase II Head and neck cancer
  • Discontinued Bladder cancer; Cancer metastases; Cervical cancer; Endometrial cancer; Leukaemia; Lung cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Pleural effusion; Prostate cancer; Sarcoma; Small cell lung cancer; Testicular cancer

Most Recent Events

  • 08 May 2017 Bristol-Myers Squibb terminates a phase I/II trial as the sponsor withdrew the study in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT00041470)
  • 30 May 2013 Biomarkers information updated
  • 17 Mar 2005 Registered as adjuvant treatment for early stage node-positive breast cancer in European Union under the mutual recognition procedure; the Netherlands acted as the reference member state (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top